Status:

WITHDRAWN

Safety and Tolerability of I-040302 in Children and Young Adults With Solitary Bone Cysts

Lead Sponsor:

Kuros Biosurgery AG

Conditions:

Bone Cysts

Eligibility:

All Genders

6-16 years

Phase:

PHASE2

Brief Summary

This is a randomised, controlled, open-label study of a single intralesional administration of I-040302 or a single bone marrow aspirate or a single steroid injection (methylprednisolone). Subjects wi...

Eligibility Criteria

Inclusion

  • Subjects 6 - 16 years of age
  • Diagnostic evidence of unicameral bone cysts based on one or more of a combination of any of the following methods:
  • Cyst fluid examination
  • Plain radiographs
  • MRI
  • Subjects with the following types of cysts:
  • Intact cysts that are either growing or at risk of fracture, requiring surgical intervention
  • Persistence of a cyst cavity following cyst fracture that has received conservative treatment/s to repair the fracture
  • Persistence of a cyst cavity despite repeated interventions
  • Subjects with bone cyst volumes \< 30 mL
  • Subjects must be appropriately communicative to verbalise pain.
  • Subjects must be able to understand and be willing to comply with the protocol procedures.
  • Subjects who have provided written informed consent to participate in the study
  • The legally authorised representative of the child must give written informed consent after the child has agreed to participate in the study.

Exclusion

  • A history of/or presence of active cancer
  • Family history of retinoblastoma
  • Indication of aneurysmal bone cyst on MRI, cyst aspiration or histology
  • Possible presence of osteosarcoma or uncertain histology
  • Systemic or localised infection at time of surgery
  • Evidence of immune-suppression
  • Evidence of hypercalcemia
  • Cyst volume \> 30 mL
  • Fracture present in the cortical bone surrounding the cyst
  • Evidence of rapid venous drainage from the cyst determined by rapid disappearance of X-ray contrast medium during the surgical process.
  • Suspected or known evidence of allergic reactions towards any of the components of I-040302
  • Known clinically significant organ or systemic diseases such that, in the opinion of the investigator, the significance of the disease will compromise the subject's participation in the study
  • Pregnant or lactating females
  • Participation in another clinical trial within 3 months prior to trial start

Key Trial Info

Start Date :

December 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2019

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00459641

Start Date

December 1 2012

End Date

July 1 2019

Last Update

July 17 2012

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.